Markets:

Overview

News

Currencies

International

Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

2.400 +0.160 (+7.14%)

Streaming Delayed Price Updated: 12:34 PM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about ImmunityBio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

November 28, 2025

Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Via Chartmill

A Fresh $16 Million Bet on ImmunityBio: What Investors Should Know ↗

November 19, 2025

A major fund just opened a multimillion-dollar position in ImmunityBio—and the move could hint at rising confidence in this clinical-stage immunotherapy pipeline.

Via The Motley Fool

Heights Capital Walks From Archer Aviation: What It Means for Investors ↗

November 19, 2025

One major investor just walked away from Archer Aviation. Here’s what that move does—and doesn’t—signal for the future of urban air mobility.

Via The Motley Fool

ImmunityBio Stock Breaks Out Of Long Slump, Tests $3 Zone: Ex-UBS Analyst Flags ‘Huge’ Bullish Signals ↗

September 17, 2025

Via Stocktwits

Heights Capital Just Ditched Its $12.5 Million AMSC Stake. Here’s What That Might Mean. ↗

November 19, 2025

One fund just walked away from American Superconductor—but the company’s role in the future of grid resiliency might be more important than any single quarterly filing suggests.

Via The Motley Fool

Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks ↗

October 22, 2025

Here's a look at the most heavily shorted stocks in the market as investors look for the next Beyond Meat.

Via Benzinga

Biotech Breakouts: 3 Stocks With Massive Upside Potential ↗

September 17, 2025

Biotech stocks are highly volatile; however, these biotech stocks have key trial results this fall that could spark sharp moves and long-term growth potential

Via MarketBeat

Not Just Opendoor & GoPro: JPMorgan Identifies 4 Emerging 'Meme Stocks' Firing Up Social Media And Hedge Fund Shorts ↗

September 12, 2025

Via Stocktwits

What's Going On With ImmunityBio Shares Tuesday? ↗

August 26, 2025

ImmunityBio shares are trading higher Tuesday after the company announced its chemotherapy-free combination showed 100% disease control results and is planning a Phase 2 trial.

Via Benzinga

IBRX Sales Soar 2,540% ↗

August 05, 2025

Via The Motley Fool

LA Times Going Public? Patrick Soon-Shiong Plans Green Bay-Style Ownership To 'Democratize' 143-Year-Old Paper ↗

July 22, 2025

Los Angeles Times owner Patrick Soon-Shiong announced plans to take the 143-year-old newspaper public within the next year.

Via Benzinga

Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday ↗

June 02, 2025

Via Benzinga

ImmunityBio Short Interest Hits 2-Month High, Yet Retail Traders Bet On The Upside ↗

May 18, 2025

Retail traders showed bullish sentiment following strong Q1 revenue growth and positive clinical data for its bladder cancer drug, despite a 54% jump in short interest.

Via Stocktwits

Foot Locker And Archer Aviation Are Among Top 8 Mid-Cap Gainers Last Week (May 12-May 16): Are The Others In Your Portfolio? ↗

May 18, 2025

Top mid-cap stock performers last week: Foot Locker, Inc. (FL), Archer Aviation Inc. (ACHR), DigitalBridge Group, Inc. (DBRG), NuScale Power Corporation (SMR), Diginex Limited (DGNX), ImmunityBio, Inc....

Via Benzinga

ImmunityBio Stock Tumbles 18% After FDA Issues Refuse To File Letter: But Retail’s Positive ↗

May 05, 2025

ImmunityBio received an RTF letter regarding a supplemental biologics license application it filed for the use of ANKTIVA plus Bacillus Calmette-Guerin (BCG) in a specific case scenario of non-muscle...

Via Stocktwits

12 Health Care Stocks Moving In Monday's Intraday Session ↗

May 05, 2025

Via Benzinga

ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug ↗

May 05, 2025

ImmunityBio's ANKTIVA sBLA for papillary bladder cancer was rejected by the FDA despite prior support, prompting the company to request urgent talks.

Via Benzinga

Netflix, CNA Financial And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

May 05, 2025

Via Benzinga

Concentrix Posts Better-Than-Expected Earnings, Joins Soleno Therapeutics, Petco Health and Wellness, MillerKnoll And Other Big Stocks Moving Higher On Thursday ↗

March 27, 2025

Via Benzinga

ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug ↗

March 06, 2025

HC Wainwright initiates coverage on ImmunityBio with a Buy rating, citing Anktiva's growth potential. The firm projects $4.3 billion in sales, up from $137M in 2025.

Via Benzinga

This Tourmaline Bio Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday ↗

March 06, 2025

Via Benzinga

Tesla Rebounds While Tariffs Weigh On Manufacturing: What's Driving Markets Monday? ↗

March 03, 2025

Stocks fell broadly on Monday to start the month of March with all three major indices red in midday trading. Investors digested a decline in February's ISM Manufacturing PMI data which fell to 50.3%,...

Via Benzinga

ImmunityBio Surges On FDA Green Light For Expanded Bladder Cancer Vaccine Access — Retail Buzz Intensifies ↗

February 20, 2025

The company said that Merck’s TICE BCG shortages have created a significant hurdle for bladder cancer treatment.

Via Stocktwits

Garmin Posts Better-Than-Expected Results, Joins SolarEdge Technologies, Compass, Appian And Other Big Stocks Moving Higher On Wednesday ↗

February 19, 2025

Via Benzinga

Tesla, Nvidia, GM And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

February 03, 2025

Via Benzinga

ImmunityBio Stock Soars On BeiGene Tie-Up, Supply Deal: Retail Gets Dose Of Optimism ↗

January 29, 2025

The study will evaluate a combination therapy using BeiGene’s tislelizumab and ImmunityBio’s Anktiva for certain patients with advanced or metastatic non-small cell lung cancer

Via Stocktwits

Brinker International Posts Upbeat Results, Joins F5, T-Mobile US, Starbucks And Other Big Stocks Moving Higher On Wednesday ↗

January 29, 2025

Via Benzinga

IonQ, H&E Equipment Services And ImmunityBio Are Among Top Mid Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio? ↗

January 19, 2025

Explore this week's top-performing mid-cap stocks, including H&E Equipment Services' impressive 100.59% surge following an acquisition announcement by United Rentals. Discover why stocks like SEMrush...

Via Benzinga

ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details ↗

January 16, 2025

ImmunityBio advances NMIBC and NSCLC treatments with promising trial data and plans 2025 FDA submissions for innovative cancer therapies.

Via Benzinga

Symbotic, DouYu International, Sezzle And Other Big Stocks Moving Higher On Thursday ↗

January 16, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.